Serum relaxin levels are reduced in pregnant women with a history of recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester.
Condensation
Serum relaxin levels are reduced in pregnant women with a history of recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester.
INTRODUCTION.
Recurrent pregnancy loss (RPL) is a distressing clinical problem which affects 1% of all women. Although no cause is found in the majority of cases, it has been associated with the antiphospholipid syndromes (1), immunological "intolerance" from altered function of endometrial natural killer (NK) cells (2) , the polycystic ovary syndrome (3) and insulin resistance (4) . A common mechanism for fetal wastage in RPL is defective implantation. (2) Even when pregnancy following RPL is ultimately successful, placental function may still be compromised, with higher rates of adverse pregnancy outcomes being reported. (5) Abnormal placentation may be associated with high resistance index (RI) in the uterine artery (UA) Doppler waveform, a finding noted to have high predictive value for conditions associated with placental dysfunction such as preeclampsia, fetal growth restriction and placental abruption. (6) Several serum markers are altered in women with RPL but do not accurately predict repeat miscarriage. These markers include inhibin A (7), glycodelin (8) and microparticles (9) . When RPL is associated with the antiphospholipid (APS) and polycystic ovary (PCOS) syndromes, markers of insulin resistance (4) are impaired.
Leptin expression levels are low in women who subsequently miscarry (10) but do not discriminate between such pregnancies and others.
Relaxin (RLX) plays a key role in reproduction, being involved in implantation, embryogenesis, placental development and prelabour uterine preparation. (11, 12) Relaxin genes are over-expressed in preterm rupture of fetal membranes (13) and change with the remodelling of the extracellular matrix prior to parturition. (14) However RLX expression during pregnancy to women with a history of RPL has not been studied.
We compared RLX levels in serum and cord blood of pregnant women with a significant history of RPL to those women with no history of RPL, and determined whether serum RLX correlates with UA Doppler indices or pregnancy outcome.
MATERIALS AND METHODS

Subjects.
Twenty women with a history of RPL (defined as the loss of three or more consecutive pregnancies before 24 wks) were consecutively recruited from the pregnancy RPL clinic. This data set comprised women with idiopathic RPL, the APS, or a history of PCOS. We included only women whose RPL was not attributable to uterine tumours, uterine malformations or proven cervical weakness. A control group of 20 age-matched women with no history of RPL or an identified association with RPL was also recruited from the booking antenatal clinics. We excluded women who smoked cigarettes from the study. Sample sizes were determined on the basis of a previous study that measured serum RLX levels and demonstrated significant differences between a group of women with abnormal pregnancies and another with normal early pregnancies. (15) We estimated that 20 subjects in each study arm would detect a 10% difference in RLX levels between groups with 80% power at the Samples were transported to the laboratory immediately and centrifuged to obtain serum which was aliquoted and stored at -80°C for subsequent batch analysis. At ≥ 10 wks, fetal biometry and UA Doppler indices were measured by transabdominal ultrasound. (16) Laboratory analysis: Serum RLX was measured using the Quantikine Human Relaxin-2 Immunoassay kit (Catalog Number DRL200, R&D systems, Minneapolis, USA). This assay is based on the quantitative sandwich enzyme technique and employs a monoclonal antibody specific for Human Relaxin-2 pre-coated onto a microplate. Standards and samples are pipetted into the wells and any Relaxin-2 present is bound by the immobilized antibody. Following addition of an enzymelinked polyclonal antibody specific for Relaxin-2 a substrate solution is added to to enable colour to develop in proportion to the amount of Relaxin-2 bound in the initial step. The assay measures the concentration range 2-250 pg/mL. The inter-assay coefficient of variation (CV) for this kit is 10.2% and 5.5% for 40 and 220 pg/mL relaxin respectively, and the intra-assay CV is 4.7% and 2.3% for 34 and 206 pg/mL, respectively. All samples were blinded for the analyst and measured simultaneously.
Samples above 250 pg/mL were diluted and re-analysed. Quantitation of serum RLX has been previously described. (15, 17) Doppler studies: Maternal UA Doppler velocimetry was evaluated using a pulsed wave technique at each visit ≥10 wks by transabdominal ultrasonography. The RI has been shown to be the most repeatable and least variable of the UA Doppler indices. (16) . The average RI of the left and right UA Doppler waveform was used for tests of association. The presence of a dicrotic notch in either or both uterine arteries was also used compare RLX levels in both study groups. All clinical details, including the pregnancy outcome for both groups, were recorded.
Outcome measures:
The primary outcome measure was serum RLX and UA RI indices. Clinical outcomes that were tested for association with serum RLX and uterine RI were spontaneous miscarriage, premature delivery before 34 wks gestation, small for gestational age (birth weight less than the 10th customized centile for gestation, (18)), placental abruption and stillbirth.
Data analysis: Serum RLX and UA Doppler indices were compared by one-way ANOVA, the student t-test or the Mann-Whitney U test with appropriate post hoc correction (the Bonferroni test) for repeated measures and multiple comparisons.
Binary logistic regression analyses and the area under the Receiver Operator Characteristic (ROC) Curves were used to test association between RLX and UA RI and clinical outcome variables. Where data regarding cord blood RLX were missing a listwise deletion approach was adopted for analysis.
RESULTS:
General clinical and laboratory details. Table 1 summarises the clinical details of all participants and the outcome of their pregnancies. Of the 20 participants with a history of RPL, 12(60%) had idiopathic RPL, 5(25%) had the APS, and 3(15%) had the PCOS associated with suspected luteal phase deficiency. All those with the APS were treated with low molecular weight heparin (LMWH) and low-dose aspirin throughout pregnancy. There was no significant difference in the rates of preterm birth, prelabour rupture of fetal membranes and miscarriage between study groups and between aetiological association subtypes in women with RPL.
Serum relaxin levels did not differ with maternal gravidity or parity. At all gestational time points, except at 6-8 wks, RLX was significantly lower in the RPL compared to the NRPL group (Table 1) . Amongst women with RPL serum RLX levels did not differ by cause of miscarriage or by treatment with aspirin or LMWH (data not shown). In NRPL but not RPL, RLX at 6-8 wks markedly correlated with levels at 12 and 20 wks gestation.
Stepwise logistic regression analysis (factors included in model: maternal age and body mass index, serum relaxin) demonstrated that serum RLX in RPL was lower than in NRPL group at 10-12wks gestation (regression coefficient -1.1, SE 0.5, OR 0.33, 95% CI 0.12, 0.95, P < 0.05), at 20 wks gestation (regression coefficient -2.0, SE 0.9, OR 0.14, 95% CI 0.03, 0.75, P < 0.05), and at 34 wks gestation (regression coefficient -1.3, SE 0.7, OR 0.26, 95% CI 0.07, 1.06, P = 0.05). The association between low RLX and a history of RPL is depicted in Figure 1 as Receiver Operator Characteristic (ROC) curves: at 10-12 wks gestation RLX ≤ 1.7ng/ml was best associated with a history of RPL [sensitivity 95%, specificity 42%, LR+ 1.64 95% CI 1.0 -2.8, LR-0.12, 95% C1 0.02 -0.8, P < 0.05)] whilst at 20 wks gestation RLX ≤ 0.7ng/ml was best associated with a history of RPL [sensitivity 79%, specificity 61%, LR+ 2.0 95% CI 1.3 -3.1, LR-0.3 95% C1 0.3 -1.0, P < 0.01)]. Although mean RLX was lower in RPL than NRPL at 6-8 and at 34 wks, the levels were not significantly associated with a history of RPL.
Correlation of serum RLX levels with uterine artery resistance index. This is summarised in Table 2 . At 10-12 wks gestation there was moderate positive correlation (correlation coefficient between 0.4 and 0.6) between the average UA RI and serum RLX for both RPL and NRPL (Figure 2 ). The incidence of uni-or bilateral notching did not differ between RPL and NRPL (Table 1 ). However at 10-12 wks mean ± SE serum RLX was higher in the NRPL group with UP notching (2.1±0.4 ng/ml) compared to those without UP notching (1.3±0.2 ng/ml, P < 0.05), but did not differ by notching in those with a history of RPL (1.1±0.2 vs. 0.9±0.2 ng/ml). Similarly at 20 wks gestation serum RLX was higher in the NRPL group with UP notching (2.1±0.7 ng/ml) compared to those without UP notching (0.95 ± 0.1 ng/ml, P < 0.05) but did not differ in those with a history of RPL (0.6 ± 0.1 vs. 0.4 ± 0.21 ng/ml). In neither group did RLX differ with UA notching at 34 wks gestation. In both groups UA pulsatility index did not correlate with serum RLX at any gestation.
Serum RLX levels and pregnancy outcomes.
Serum RLX at 34 wks gestation was not significantly different in women who had prelabour rupture of membranes (mean ± SE 0.8 ±0.1) compared to women who went into labour with intact membranes (0.9 ±0.2 ng/ml), and did not correlate with fetal birth weight or gestational age at delivery for either group.
Cord blood relaxin levels. Cord blood was obtained in 15 (75%) RPL and 13 (60%) NRPL participants: RLX levels were 4-fold higher in the RPL group than the NRPL group but this did not attain statistical significance (Table 1) We noted a 4-fold increase in cord blood RLX levels in the women with a history RPL compared to those without. However our data only approached statistical significance possibly because our sample size was small. It may be hypothesized that deranged maternal RLX metabolism associated with RPL leads to a compensatory increase in fetal relaxin expression through as yet unidentified regulatory feedback mechanisms similar to the fetal hyperinsulinaemia/hypoglycaemic response to maternal hyperglycaemia. Interestingly relaxin belongs to the insulin family of peptide hormones.
We observed modestly increased cord blood relaxin levels in the subset of the RPL group who had prelabour membrane rupture. A similar increase has been described in preterm decidual tissue and placental syncytiotrophoblast from women with preterm premature rupture of membranes compared to those with intact membranes.
(13) Our study of systemic rather than local tissue RLX levels may have precluded identification of any relationship between RLX expression and timing of fetal membrane rupture.
We studied the expression levels of human RLX2 rather than RLX1 because only the former isoform appears to have a functional role in reproductive tract tissue. (26) . It is unlikely that the serum RLX that we measured originated from non-gestational tissues as gestational relaxin is only expressed in placental syncytiotrophoblast, decidua, and corpus luteum. (27) In the nonpregnant state, relaxin was only demonstrable in the corpus luteum and secretory phase endometrium and not in myometrium, cervix, vagina, and Fallopian tubes.
We did not exclude women whose previous miscarriages were due to embryonic chromosomal aberrations because this information was not always available. Such chromosomal aberrations in past pregnancy losses may have confounded the results. Only one patient in our study group subsequently miscarried, suggesting an extremely high live birth rate or 95%. The reason for the highly successful birth outcome in our cohort is unclear but may be attributable in part to our care philosophy that spans from conception to birth in one unified service provided by specialist nurses, midwives, gynaecologists with an interest in RM and fetal medicine specialists.
In conclusion, we have demonstrated that serum relaxin levels are reduced across all gestations of viable pregnancies to women with a history of RPL. Taken together with studies that show reduced relaxin levels in abnormal and non-viable pregnancies, our data suggest that dysregulation of RLX functional expression may play a role in habitual early pregnancy failure possibly by suppressing endometrial and placental angiogenesis. Further studies are required to explain these observations.
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